PMID- 19895922
OWN - NLM
STAT- MEDLINE
DCOM- 20100203
LR  - 20131121
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 28
IP  - 3
DP  - 2010 Jan 8
TI  - Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate 
      vaccine in children 2-10 years of age.
PG  - 657-63
LID - 10.1016/j.vaccine.2009.10.104 [doi]
AB  - Meningococcal disease incidence is highest in infants, but a significant burden 
      of disease also occurs in children. In this Phase II, single-centre US study, 619 
      healthy children (2-10 years of age) received one dose of an investigational 
      quadrivalent meningococcal CRM(197)-conjugated vaccine (MenACWY-CRM) or a 
      licensed quadrivalent meningococcal polysaccharide vaccine (MPSV4). 
      Immunogenicity was assessed using the serum bactericidal assay with human 
      complement (hSBA) at 1 and 12 months post-vaccination. Local and systemic 
      reactions were recorded for 7 days, all adverse events (AEs) for 1 month, and 
      medically significant and serious AEs (SAEs) for 12 months post-vaccination. For 
      all four serogroups, more MenACWY-CRM recipients achieved an hSBA titre >or=1:4 
      at 1 month post-vaccination (A: 82%; C: 83%; W-135: 95%; Y: 91%) compared with 
      the group that received MPSV4 (A: 45%; C: 66%; W-135: 71%; Y: 61%); this 
      difference persisted through to 12 months post-vaccination. Both vaccines were 
      well tolerated. In children 2-10 years of age, MenACWY-CRM induced a higher 
      immune response than that of MPSV4, and was well tolerated.
FAU - Black, S
AU  - Black S
AD  - Center for Global Child Health, Cincinnati Children's Hospital, Cincinnati, Ohio, 
      USA. steven.black1@cchmc.org
FAU - Klein, N P
AU  - Klein NP
FAU - Shah, J
AU  - Shah J
FAU - Bedell, L
AU  - Bedell L
FAU - Karsten, A
AU  - Karsten A
FAU - Dull, P M
AU  - Dull PM
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20091104
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (Antibodies, Bacterial)
RN  - 0 (Meningococcal Vaccines)
RN  - 0 (Vaccines, Conjugate)
RN  - 9007-36-7 (Complement System Proteins)
SB  - IM
MH  - Antibodies, Bacterial/blood
MH  - Blood Bactericidal Activity
MH  - Child
MH  - Child, Preschool
MH  - Complement System Proteins/immunology
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Female
MH  - Humans
MH  - Male
MH  - Meningococcal Infections/*prevention & control
MH  - Meningococcal Vaccines/*administration & dosage/*immunology
MH  - Time Factors
MH  - United States
MH  - Vaccines, Conjugate/administration & dosage/immunology
EDAT- 2009/11/10 06:00
MHDA- 2010/02/04 06:00
CRDT- 2009/11/10 06:00
PHST- 2009/02/10 00:00 [received]
PHST- 2009/10/14 00:00 [revised]
PHST- 2009/10/19 00:00 [accepted]
PHST- 2009/11/10 06:00 [entrez]
PHST- 2009/11/10 06:00 [pubmed]
PHST- 2010/02/04 06:00 [medline]
AID - S0264-410X(09)01655-7 [pii]
AID - 10.1016/j.vaccine.2009.10.104 [doi]
PST - ppublish
SO  - Vaccine. 2010 Jan 8;28(3):657-63. doi: 10.1016/j.vaccine.2009.10.104. Epub 2009 
      Nov 4.